Area of research
Radiology, Nuclear Medicine and Imaging · Immunology
Research interest
Research interests include Monoclonal and Polyclonal Antibodies Research, Immunotherapy and Immune Responses, Veterinary Oncology Research, and Cancer Research and Treatments.
Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells
Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity
CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs
Bivalent target-binding bioPROTACs induce potent degradation of oncogenic SHP2
Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells
Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies
Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2
Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression
Tregs constrain CD8 <sup>+</sup> T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapy
Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity
Maximizing response to intratumoral immunotherapy in mice by tuning local retention
Intratumoral nanobody–IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice
Intratumorally anchored cytokine therapy
Co‐Anchoring of Engineered Immunogen and Immunostimulatory Cytokines to Alum Promotes Enhanced‐Humoral Immunity
Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity
High-throughput phenotypic screen and transcriptional analysis identify new compounds and targets for macrophage reprogramming
Lack of CD8 <sup>+</sup> T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer
Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice
Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity
Pharmacokinetic tuning of protein–antigen fusions enhances the immunogenicity of T-cell vaccines
Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor
Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy
Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models
What, Why, Where, and When: Bringing Timing to Immuno-Oncology
Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
Reduction of Nonspecificity Motifs in Synthetic Antibody Libraries
An engineered protein antagonist of K-Ras/B-Raf interaction
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies